Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.41 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.41 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.41 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.41 |
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.41 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.41 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.41 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605610 | 0.85 | EPHX1 (0.68) | EPHX1PPARGPPARDPPARASLC6A2 | |
| SCHEMBL3277794 | 0.81 | EPHX1 (0.43) | EPHX1ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL5177167 | 0.81 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL4028048 | 0.81 | EPHX1 (0.43) | EPHX1 | |
| SCHEMBL5177355 | 0.80 | L3MBTL1 (0.49) | EPHX1MEN1LMNAKMT2A | |
| SCHEMBL4027743 | 0.80 | ESR1 (0.58) | EPHX1LMNA | |
| SCHEMBL3271868 | 0.80 | EPHX1 (0.51) | EPHX1ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL3945921 | 0.80 | MEN1 (0.47) | EPHX1PPARGPPARDPPARAMEN1 | |
| Hydrochloric Acid SCHEMBL3950180 | 0.80 | EPHX1 (0.42) | EPHX1ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL3939264 | 0.80 | EPHX1 (0.49) | EPHX1ADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | claimed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | EPHX1 1260/4885PPARG 520/4885PPARD 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.